These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 30941571)

  • 21. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
    Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
    Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reprint of: Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
    Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
    J Am Pharm Assoc (2003); 2024; 64(4S):102156. PubMed ID: 39127933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis.
    Luo C; Chen F; Chen YH; Zhao CF; Feng CZ; Liu HX; Luo DZQ
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2637-2653. PubMed ID: 33829451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
    Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
    Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series.
    Bradshaw PG; Keegan S; Foertsch M; Yang GL; Ngwenya LB; Srinivasan V
    J Thromb Thrombolysis; 2022 Aug; 54(2):295-300. PubMed ID: 35507109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre.
    Milioglou L; Liao K; Traeger J; McKenzie C; Burrelli C; Khunayfir AKB; Makii J; Hoffer A
    Blood Coagul Fibrinolysis; 2022 Jul; 33(5):261-265. PubMed ID: 35153278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
    Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
    Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor-Associated Bleeding: A Retrospective Study.
    Wilsey HA; Bailey AM; Schadler A; Davis GA; Nestor M; Pandya K
    J Intensive Care Med; 2021 May; 36(5):597-603. PubMed ID: 32242482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
    Maragkos GA; Nelton EB; Richter S; Stippler M
    World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study.
    Singer AJ; Concha M; Williams J; Brown CS; Fernandes R; Thode HC; Kirchman M; Rabinstein AA
    West J Emerg Med; 2023 Sep; 24(5):939-949. PubMed ID: 37788035
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.
    Tao J; Bukanova EN; Akhtar S
    J Intensive Care; 2018; 6():34. PubMed ID: 29942519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-administration of Four-Factor Prothrombin Complex Concentrate With Andexanet alfa for Reversal of Nontraumatic Intracranial Hemorrhage.
    Pathan S
    Hosp Pharm; 2024 Aug; 59(4):394-406. PubMed ID: 38919755
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
    Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
    Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
    Dobesh PP; Fermann GJ; Christoph MJ; Koch B; Lesén E; Chen H; Lovelace B; Dettling T; Danese M; Ulloa J; Danese S; Coleman CI
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102192. PubMed ID: 37753225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
    Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
    J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage.
    Irizarry-Gatell VM; Bacchus MW; De Leo EK; Zhang Y; Lagasse CA; Khanna AY; Harris NS; Zumberg MS
    Blood Coagul Fibrinolysis; 2024 Apr; 35(3):94-100. PubMed ID: 38358898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
    Rogers KC; Finks SW
    Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries.
    Sadek E; Curtiss W; Andrews J; Hecht J
    Emerg Med J; 2024 Feb; 41(3):162-167. PubMed ID: 38267194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.